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UbiqutinAbstract The Tribbles (TRIB) family of pseudokinase proteins has been shown to play key roles in cell
cycle, metabolic diseases, chronic inflammatory disease, and cancer development. A better understanding
of the mechanisms of TRIB pseudokinases could provide new insights for disease development and help
promote TRIB proteins as novel therapeutic targets for drug discovery. At the 2nd International
Symposium on Tribbles and Diseases held on May 7–9, 2018 in Beijing, China, a group of leading
Tribbles scientists reported their findings and ongoing studies about the effects of the different TRIB
proteins in the areas of immunity, metabolism, fundamental cell biology and cancer. Here, we summarize
important and insightful overviews from 4 keynote lectures, 13 plenary lectures and 8 short talks that took
place during this meeting. These findings may offer new insights for the understanding of the roles of
TRIB pseudokinases in the development of various diseases.
& 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Tribbles (TRIB) pseudokinases control multiple aspects of
eukaryotic cell biology and have evolved unique features distin-
guishing them from all other eukaryotic protein kinases1. Under-
standing the roles of Tribbles proteins, which include human
TRIB1, TRIB2 and TRIB3, in disease initiation and development
provides better opportunities for targeted-therapies in the future.
Due to the absences of the conserved kinase catalytic domain or
ATP binding sites, TRIBs are described as pseudokinases2. TRIBs,
as key adaptors, play important roles to regulate several important
signaling pathways and control the quality of many proteins3.Recent advancements focused on the roles of TRIBs in immunol-
ogy, metabolism, fundamental cell biology and tumorigenesis4–7.
Emerging evidences indicates that targeting TRIBs might also
provide therapeutic opportunity for many different diseases8,9.
The 2nd International Symposium on Tribbles and Diseases was
held between May 7–9, 2018 in Beijing, China. This international
meeting was sponsored by the Chinese Academy of Medical Sciences
(CAMS) and State Key Laboratory of Bioactive Substance and
Function of Natural Medicines (BSFNM). The organizers invited
worldwide scientists who focused on the research of TRIBs protein in
many different perspectives. The meeting was composed of three
major sessions, including “Tribbles and Immunity & Metabolism”
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Fundamental Cell Biology” chaired by Dr. Karen Keeshan and Prof.
Takuro Nakamura, and “Tribbles and Cancer” chaired by Prof.
Patrick Eyers and Prof. Leonard Dobens.
The meeting consisted of 4 keynote lectures, 13 plenary lectures
and 8 short talks. This report summarizes the major highlights
presented at the 2nd International Symposium on Tribbles and
Diseases. With a focus on the most recent advances in the fields of
immunity, metabolism, fundamental cell biology, and cancer, the
programs covered a wide range of important topics, including
atherosclerosis, obesity, fibrotic diseases, inflammation, normal
blood cells differentiation, signaling in Drosophila and Caenor-
habditis elegans development, metabolism and signaling in cancer,
metastasis, and protein-quality control.Figure 1 ANGPTL4:14-3-3 signaling axis integrates protein–protein
interactome with kinome network to synchronize cancer cell metabolic
activities in EMT. Epithelial‐to‐mesenchymal transition (EMT) plays2. Opening keynote lecture: “The interface between signaling
and metabolism in cancer” by Dr. Arkaitz Carracedo
Dr. Jiang, the Director of the Institute of Materia Medica (IMM,
Beijing, China) at the Chinese Academy of Medical Sciences (CAMS)
and Peking Union Medical College (PUMC), greeted all the attendees
at the international Tribbles meeting, which was hosted by Dr.
Zhuowei Hu's group from IMM. Dr. Endre Kiss-Toth, co-chairman
of the organizing committee, welcomed the worldwide attendees, and
then introduced Dr. Arkaitz Carracedo from Spain to present the first
keynote lecture. Dr. Carracedo's laboratory10–13 is focusing on
investigating the contribution of cell metabolism to cancer cell biology,
and the development of more selective and effective therapies for
cancer. Dr. Carracedo presented his recent work on metabolic
reprogramming in prostate cancer. Cellular transformation and cancer
progression are accompanied by metabolic changes, and there are
different strategies to study metabolism in the context of cancer. Firstly,
bioinformatics analysis is a good strategy to uncover novel metabolic
regulators. The function of the transcriptional co-activator PGC1A as a
prostate tumor suppressor could be contextualized to promote the
exploitation of publicly available transcriptomics datasets in the context
of Tribbles family proteins. Secondly, genetic mouse model is a faithful
model of the human disease. The data on the metabolomics analysis of
murine models and human prostate cancer specimens led to the
discovery of a novel molecular connection between the oncogenic
mTORC1 pathway and polyamine biosynthesis12. This metabolic route
could be used to exemplify the identification of cancer relevant
therapeutic targets, as well as the complexity in the cross-talk between
cell signaling and metabolism11. At last, Dr. Carracedo emphasized the
potential of investigating the connection of oncogenic signals and
metabolic networks for the establishment of better stratification
strategies and therapeutic initiatives.crucial roles in the metastatic dissemination of carcinomas. Using
in vitro and in vivo EMT models to compliment stage-specific human
cancer biopsies, we have identified angiopoietin-like 4 (ANGPTL4) as
a molecular driver of EMT-enriched metabolic changes for EMT
competency. ANGPTL4 upregulates the expression of 14-3-3γ (herein
called the ANGPTL4:14-3-3γ axis) that ensures metabolic flexibility to
secure ample adenylate cellular energy to fuel various EMT-associated
biological processes. The elevated 14-3-3γ adaptor protein coordinates
cellular metabolic activity via interaction with tuberous sclerosis
complex 2 (TCS2) and SNAI1. The 14-3-3γ stabilizes SNAI1-
mediated repression of E-cadherin. TSC2 is an important gatekeeper
of cellular metabolism that integrates extracellular signals to direct
anabolic or catabolic activities. The 14-3-3γ:TSCS939 complex
formation ensure the continued inhibition of TSC2S93.3. Session on “Tribbles and Immunity and Metabolism” chaired
by Dr. Warren Pear and Dr. Zhuowei Hu
3.1. Key lecture on “angiopoietin-like 4 protein in cancer meta-
stasis” by Dr. Naguan Soon Tan
Metastasis accounts for most cancer related deaths. However,
this process remains one of the most enigmatic aspects of the
disease14. The epithelial-mesenchymal transition (EMT) is
associated with key transcriptional changes during the metastatic
process. Dr. Naguan Soon Tan focused on the requirement of
metabolic reprogramming for epithelial-mesenchymal transition.He first introduced the in vitro models of EMT from his recent
study15, which identified angiopoietin-like 4 (ANGPTL4) as a
key player that coordinates an increase in cellular energy flux
crucial for EMT via an ANGPTL4/14-3-3γ signaling axis
(Fig. 1). ANGPTL4, a secreted glycoprotein, binds to specific
integrins, cadherins and claudins, but not Tie receptors and
VEGFR16. ANGPTL4 was found to protect against severe
proinflammatory effects of saturated fats17. Elevated ANGPTL4
expression is found in many cancer subtypes, including breast
cancer, lung cancer and gastric cancer15,18. Dr. Tan discussed
how augmented energy charge status enhances metastasis.
ANGPTL4 knockdown was found to suppress an adenylate
energy charge elevation, delay EMT, and reduce cancer metas-
tasis to the lung and liver. Unbiased kinase inhibitor screens and
ingenuity pathway analysis revealed that ANGPTL4 regulates
the expression of 14-3-3γ adaptor proteins via the phosphatidy-
linositol-3-kinase/AKT and mitogen-activated protein kinase
signaling pathways, which culminate in the activation of
transcription factors, CREB, cFOS and STAT3. Moreover, an
increase in an ‘adenylate energy charge’ by ANGPTL4 protein
enhances EMT by inducing 14-3-3γ expression. The ANGPTL4/
14-3-3 signaling axis consolidated cellular bioenergetics and
stabilized critical EMT proteins to coordinate energy demand
and enhanced EMT competency and metastasis, through inter-
action with specific phosphorylation signals on target proteins.
Dr. Tan ended his talk by sharing some thoughts about the new
ANGPTL4/14-3-3 signaling axis during the EMT.
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function and kidney transplantation” by Yodit Feseha
Regulatory CD4þ T lymphocytes (Treg) are key players in the
control of the immune system and thus play important roles in
allograft survival in different experimental models and in human
renal transplantation. In renal transplanted patients experiencing
chronic antibody-mediated rejection (CAMR), it was discovered
that a decreased blood Treg frequency associated with an
incomplete forkhead box transcription 3 (FOXP3) promoter
demethylation, the central transcription factor of Treg19. A meta-
analysis where a combination of 6 genes were able to discrimi-
nates tolerant patients from stable patients20,21. The TRIB1 gene
was demonstrated to serve as a diagnostic biomarker for CAMR22
and TRIB1 is over-expressed in Treg compared to counterpart
naïve T cells and interacts in the nucleus with FOXP323. TRIB1
may participate as part of a multiprotein regulatory complex driven
by FOXP3, and modulates a downstream transcriptional program
that is essential for Treg homeostasis, stability, proliferation and
function. In order to address the role of TRIB1 in Treg, a mouse
strain was developed with Tamoxifen conditional deletion of Trib1
specifically in Treg. While Trib1 over-expression impaired acti-
vated CD4þ lymphocytes proliferation, their preliminary results
highlighted Trib1 deletion in transgenic mice was associated with
expression alterations of several key genes.
3.3. Plenary lecture on “Trib1 regulates eosinophil fate and
identity by restraining the neutrophil program” by Dr. Warren
Pear
The evolutionarily conserved group of TRIB pseudokinases have
been shown to regulate multiple cellular events including those
involved in normal and malignant haematopoiesis4. Like their
human counterparts, the three murine Tribbles gene homologues,
Trib1, Trib2 and Trib3 are characterized by conserved motifs,
including a pseudokinase domain and a C-terminal E3 ligase-
binding domain. Dr. Warren Pear focused on the role of TRIB
(murine Tribbles homologues) proteins in mammalian haemato-
poiesis and leukaemia. The TRIB proteins show divergent
expression in haematopoietic cells, probably indicating cell-
specific functions. The roles of the TRIB proteins in oncogenesis
are also varied and appear to be tissue-specific. In their ongoing
study, Dr. Pear utilized Trib1 KO mice to identify the roles of
TRIB1 in several cell types. In particular, the function of TRIB1
was investigated in mediating eosinophil lineage choice and
differentiation from multipotent hematopoietic progenitors.
3.4. Short talk on “Myeloid TRIB1 controls experimental ather-
osclerosis” by Dr. Jessica Johnston
In Genome Wide Association Studies (GWAS), Trib1 was
identified as a potential regulator of plasma lipid levels and a risk
factor for myocardial infarction (MI)24–26. Studies using Trib1 full
body- and liver-specific knockout mice had shown that hepatic
expression of Trib1 reduces circulating lipids27. Additionally,
Trib1 had been shown to be a regulator of alternatively activated
macrophage polarization. However, no study directly evaluated the
role of myeloid Trib1 (mTrib1) in atherogenesis. Myeloid-Trib1
deficient (mTrib1KO) and overexpression (mTrib1Tg) mouse strains
were used to determine the role of mTrib1 in atherosclerosis. Todistinguish between metabolic and inflammatory drivers of ather-
osclerosis, bone marrow from these strains were transplanted into
lethally irradiated ApoE / mice and fed on a Western diet for 12
weeks. Based on their initial results, Dr. Jessica Johnston
suggested that Trib1 is a potent regulator of atherosclerosis via
regulating oxLDL uptake and subsequent foam cell formation in
plaque macrophages.
3.5. Plenary lecture on “Impact of Tribbles 1 and 3 on meta-
bolism and inflammation” by Dr. Marcel Scheideler
The Tribbles genes consists of three highly conserved mammalian
homologues, each with its own distinctive functional properties in
metabolism, inflammation and metabolic pathologies, including
key roles in diabetes and obesity. TRIB3 levels are induced in liver
under fasting conditions, as well as in livers of diabetic db/db
mice. Hepatic overexpression of TRIB3 in amounts comparable to
those in db/db mice promoted hyperglycemia and glucose intol-
erance. TRIB3 has been identified as critical regulator of hepatic
glucose homeostasis via negatively modulating AKT, thus con-
tributing to insulin resistance in individuals with susceptibility to
type 2 diabetes28,29. In white adipose tissue (WAT), TRIB1 was
found to be significantly elevated in expression upon acute and
chronic inflammation. In adipocytes, TRIB1 is under the control of
NF-κB cytokine signaling, and TRIB1 controls pro-inflammatory
gene expression in a cell-autonomous manner. Dr. Marcel Schei-
deler suggested that TRIB1 may be involved in the communication
between metabolic (adipocytes) and immune cells in WAT,
thereby contributing to WAT inflammation in response to acti-
vated WAT-associated immune reactions. As pro-inflammatory
signaling is typically increased in sepsis, insulin resistance, and
obesity-related type 2 diabetes, the cytokine-inducible TRIB1
function in WAT might provide a molecular rationale for the
amplification of systemic inflammation. Moreover, TRIB1 hap-
loinsufficiency protects against high-fat diet-induced obesity,
indicating an impact on energy metabolism.
3.6. Short talk on “TRIB3, a regulator of lipid handling and
metabolic syndrome” by Zabran Ilyas
Obesity is a major risk factor for many facets of metabolic diseases
including diabetes, hypertension and cardiovascular disease30.
TRIB3 has been implicated in these metabolic processes30.
However, current insight into the role of TRIB3 in various organs
remains limited. A systemic approach was used for the first time
on a whole body Trib3ko mice to decipher a role for Trib3 in
metabolic dysfunction. A Trib3 full body knockout (Trib3ko)
mouse was generated using a gene-trap system that disrupts the
transcription of Trib3 mRNA. Comparative gene expression
microarray analysis was performed on the liver, adipose and
muscle tissues from Trib3ko and wild-type littermates. Male
Trib3ko mice were obese with elevated plasma levels of HDL
and total cholesterol. These knockout mice also displayed a fatty
liver phenotype, an increased macrophage influx and dysregulated
proliferation in the adipose tissue. Microarray analysis revealed
multiple metabolic pathways in the liver, adipose, and muscle
tissues were altered, suggesting a dysregulated inter-organ com-
munication underpinning obesity. Several key signaling regulators
were identified alternation in the liver of Trib3ko compared with
wild-type mice as evidenced by qPCR and Western blots. Mr.
Tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer 447Zabran Ilyas suggested that Trib3 plays an important part in inter-
organ communication that regulates lipid homeostasis.
3.7. Plenary lecture on “Tribbles-1, a GWAS locus for cardio-
metabolic traits, exhibits adipose-specific regulation of plasma
cholesterol, triglycerides, and adiponectin” by Dr. Robert Bauer
TRIB1, a novel mediator of plasma lipids and coronary artery
disease in humans, was identified through genome-wide associa-
tion studies31,32. Subsequent in vivo mouse work confirmed that
hepatic Trib1 participates in the regulation of plasma lipids, yet
little is known about metabolic roles for extra-hepatic Trib125,27.
SNPs near the TRIB1 gene are significantly associated with
circulating adiponectin levels in humans, suggesting a functional
role for TRIB1 in adipose tissue. In light of this observation, the
adipose-specific Trib1 KO mice (Trib1_ASKO) were generated. It
was found that Trib1_ASKO mice had altered plasma adiponectin
levels. Interestingly, chow-fed Trib1_ASKO mice also exhibited
altered total, HDL, and non-HDL cholesterol, as well as plasma
triglycerides as compared to WT mice. Ongoing studies aimed to
elucidate the mechanism through which adipose Trib1 protein
regulates plasma cholesterol metabolism and adiponectin levels.
Finally, an observed role for Trib1 in both adipose and hepatic
regulation of plasma lipids suggested that common SNPs in the
8q24 region alter TRIB1 expression in both tissues. Using
ENCODE data, they identified 10 candidate genomic regions
and are currently testing them for transcriptional enhancer activity.
Additionally, they are using pooled CRISPR library screens to
understand tissue-specific regulation of TRIB1 in adipocytes and
hepatocytes. Dr. Robert Bauer presented the first in vivo validation
of the human genetic association between TRIB1 and plasma
adiponectin, and provided evidence suggesting that adipose TRIB1
contributed to the genetic associations observed in humans
between TRIB1 and multiple metabolic parameters.
3.8. Plenary lecture on “TRIB3 in erythroid and megakaryocytic
differentiation” by Dr. Jorge Erusalimsky
The platelet-lowering agent anagrelide acts as a selective inhibitor
of megakaryopoiesis33,34. Anagrelide targets a cellular event
involved specifically in the megakaryocyte (MK) differentiation
programme33,35. In a follow-up study, 328 annotated genes
differentially regulated by anagrelide were identified. Many genes
associate with platelet functions and the control of gene transcrip-
tion. Prominent among the latter was TRIB3, whose expression
increased in the presence of anagrelide36. Anagrelide induced the
phosphorylation of eIF2, and increased the expression of the
transcription factor ATF4, a known inducer of the TRIB3 gene.
Salubrinal, an effector of this pathway, also inhibited MK
differentiation. These findings linked signaling through eIF2α/
ATF4 to the anti-megakaryopoietic activity of anagrelide. Silen-
cing TRIB3 reduced the ability of anagrelide to inhibit MK growth.
Furthermore, TRIB3 was identified as a negative modulator of
megakaryocytopoiesis in their recent study by using cellular model
systems of haematopoietic lineage differentiation37. In primary
cultures derived from human haematopoietic progenitor cells,
thrombopoietin-induced megakaryocytic differentiation led to a
time- and dose-dependent decrease in TRIB3 mRNA levels. In the
haematopoietic cell line UT7/mpl, silencing of TRIB3 increasedbasal and thrombopoietin-stimulated megakaryocyte antigen
expression, as well as basal levels of ERK1/2 phosphorylation.
In primary haematopoietic cell cultures, silencing of TRIB3
facilitated megakaryocyte differentiation. Based on the in vitro
identification of TRIB3 as a negative regulator of megakaryocy-
topoiesis, Dr. Jorge Erusalimsky suggested that this gene could be
important for the regulation of platelet production in vivo36,37. At
the end of his presentation, Dr. Erusalimsky also shared some
thoughts about the role of TRIB3 in erythroid and megakaryocytic
differentiation.
3.9. Short talk on “Upregulation of Tribbles 1 in Oxidative Stress”
by Dominika Grzesik
TRIB1 has been detected in atherosclerotic lesions. Human
monocyte-derived macrophages (MDM) was found with the
highest TRIB1 RNA content contained, relative to those with the
lowest TRIB1 RNA content, an enrichment of genes involved in
maintaining redox homeostasis. Conversely, mice with redox
perturbation (Nnt /) have increased adrenal Trib1 RNA levels
at 18 months of age, coincident with increased levels of reactive
oxygen species. The relationship was discovered between Nnt
deficiency and Trib1 in adrenal cells and macrophages. These
initial results provided the first evidence of cell-specific Trib1
upregulation in response to chronic oxidative stress in adrenal cells
and macrophages.4. Session on “Tribbles and Fundamental Cell Biology” chaired
by Dr. Karen Keeshan and Dr. Takuro Nakamura
4.1. Key lecture on “Substrate-induced ubiquitin ligase acti-
vation by the TRIB1 pseudokinase” by Dr. Peter Mace
Dr. Peter Mace's research is focused on understanding signaling
networks that regulate how cells respond to stress. They are
particularly interested in how phosphorylation and ubiquitination
act as protein switches to control cell death and proliferation.
TRIB1 can drive leukaemia development and is overexpressed
across a range of other cancers38. The Tribbles family of
pseudokinases recruit substrates—including metabolic proteins
and transcription factors—to the COP1 ubiquitin ligase for
ubiquitin-mediated protein degradation. CCAAT-enhancer binding
protein (C/EBP) family transcription factors are a particularly
relevant class of Tribbles-COP1 substrate in adipocyte and
myeloid development, and in acute myeloid leukaemia. Several
crystal structures of TRIB1 including an autoinhibited state and the
TRIB1 pseudokinase in complex with the Tribbles recognition
degron from C/EBPα were recently identified (Fig. 2). These
structures showed that TRIB1 underwent a significant change
relative to its substrate-free structure, with C/EBPα binding as a
pseudo-substrate. Importantly, substrate-induced changes in
TRIB1 engaged an allosteric network that linked substrate binding
to release of the COP1 binding-motif of TRIB1 and formation of
the COP1-TRIB1 ubiquitin E3 ligase complex. Such a model was
consistent with biochemical experiments and molecular dynamics
simulations. These findings offered a view of pseudokinase
regulation with strong parallels to canonical kinase regulation
and raised the possibility of small molecules targeting different
conformations of Tribbles pseudokinases39.
Figure 2 Schematic depiction of substrate-induced activation of
TRIB1. In the substrate-free state, TRIB1 is able to sequester its own
C-terminal COP1-binding motif. C/EBP binds as a pseudo-substrate and
triggers conformational changes that release autoinhibition of TRIB1,
favoring assembly of the TRIB1-COP1 complex.
Bing Cui et al.4484.2. Plenary lecture on “Repurposing covalent EGFR/HER2
inhibitors for on-target degradation of human Tribbles 2 (TRIB2)
pseudokinase” by Dr. Patrick Eyers
Dr. Patrick Eyers first explained the difference between kinases
and pseudokinases. A major challenge associated with biochemical
and cellular analysis of pseudokinases is a lack of target-validated
small molecules with which to probe their molecular function2.
Human TRIB2 is a cancer-associated pseudokinase with a diverse
interactome, which includes the canonical AKT signaling module,
with which it interacts directly. There are also several lines of
evidence that dysregulation of TRIB2 is relevant in solid tumors
and myeloid- and lymphoid-derived human leukemias, making it a
novel therapeutic target1,40,41. The non-canonical TRIB2 pseudo-
kinase domain contains a unique cysteine rich region and interacts
with a peptide motif in its own C-terminal tail, which was
previously shown to drive interaction with cellular E3 ubiquitin
ligases (Fig. 3). TRIB2 is a target for previously described smallFigure 3 Human Tribbles family pseudokinases. (A) Alignment of the re
binding to ATP) and the atypical C-helix of human Tribbles (TRIB1-3) pse
which lacks a β3-Lys residue, and the N-lobe C-helix of which more clo
presence of three unique Cys residues (Cys96, Cys104 and Cys106, red)
small molecules through a Thiol–Michael Addition reaction. (B) Clinically
are also shown to bind to human TRIB2. The double bond in each compomolecule protein kinase inhibitors, which were originally designed
to inhibit the canonical catalytic domain of the tyrosine kinases
EGFR/HER242. Using a thermal-shift assay, TRIB2 ligands were
discovered within the Published Kinase Inhibitor Set (PKIS), and
then a drug repurposing approach was employed to classify
ligands that either stabilize or destabilize TRIB2 in vitro. Remark-
ably, TRIB2 destabilizing agents, including the clinical covalent
drug afatinib, led to rapid TRIB2 degradation in human cells,
eliciting tractable effects on signaling and survival through direct
binding to TRIB243. These data revealed drug-leads for develop-
ment of TRIB2-degrading ligands, which could also be invaluable
for unravelling cellular mechanisms of TRIB2-based signaling.
This study highlighted that small molecule-induced protein down-
regulation through drug ‘off-targets’ might be relevant for other
small molecules which serendipitously target Tribbles pseudoki-
nases, including compounds repurposed from the clinic44.4.3. Plenary lecture on “Redundancy and specificity in Tribbles
mediated signaling” by Dr. Endre Kiss-Toth
The TRIB1 gene has been linked to several human pathologies,
including lipid disorders and cardiovascular disease. It has also
been established that TRIB1 critically regulates M2-like macro-
phage differentiation and unpublished data have linked TRIB1
expression to increased atherosclerotic plaque formation45. Pre-
vious studies reported that TRIB1 protein is produced from a
highly unstable mRNA, with a half-life shorter than 1 h, suggest-
ing it may be subject to post-transcriptional regulation. Indeed, the
TRIB1 transcript includes a long, conserved 3UTR, enriched with
miRNA-binding sites. The post-transcriptional regulation of TRIB1
by miRNAs was investigated in the context of macrophage
biology. Macrophages have been implicated in immune- and
cardio-metabolic diseases; controlling their molecular responses
through the activity of miRNAs and TRIB1 may represent an
attractive therapeutic approach. Bimolecular fluorescencegion encompassing the conserved-β3 Lys motif (which normally aids
udokinases, and the less closely-related pseudokinase STK40/SgK495,
sely resembles that of canonical protein kinases, such as PKA. The
in human TRIB2 presents an opportunity for covalent conjugation to
-approved irreversible covalent inhibitors of EGFR family kinases that
und is shown in red for clarity.
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Tribbles proteins could bind to an overlapping set of MAPK-
kinases (MAPKK) in live cells and dictated the localisation of the
subsequent complexes. Binding studies in transfected cells
revealed common regulatory mechanisms and suggested that
Tribbles and MAPKs might interact with MAPKKs in a compe-
titive manner. Computational modelling of the impact of Tribbles
on MAPK activation suggested a high sensitivity of this system to
changes in Tribbles levels, highlighting that these proteins were
ideally placed to control the dynamics and balance of activation of
concurrent signaling pathways46.
4.4. Short talk on “Computational modelling of Tribbles com-
plexes” by Juan Salamanca
Among the processes that occur in cells, direct protein–protein
interactions (PPIs) are critical for many biological functions. Proteins
do not act in isolation, and essentially all regulatory processes such as
replication, transcription and signal transduction involved in biological
responses are only made possible through multiple PPIs. It is therefore
not surprising that dysregulation of PPIs is related to diseases such as
cancer, neurodegenerative diseases, virus infection and metabolic
disorders47. In this context, TRIB pseudokinases appear as an
interesting family of proteins, involved in many PPIs. TRIB proteins
had been proposed to play roles as “scaffolds” with other kinases
(e.g., TRIB3 interacts with MEK and AKT proteins) or as regulators of
transcription factors and ubiquitylation (e.g., TRIB C-terminal motif,
COP1 and SIAH1) among others1. It is not surprising that dysregula-
tion of TRIB proteins have been implicated in a variety of human
cancers (AML, lung, hepatic and melanoma)8. Research into structure/
sequence conservation and applying computational tools such as
protein–protein docking together with experimental data will help to
elucidate how these PPIs occur at an atomic level. Currently
Salamanca's group is investigating the interactions between TRIB3
and some of its most interesting partners, the E3 ligase SIAH1 and the
kinase PKB/AKT. Each of these studies aimed to solve different
biological questions, the former related to the degradation of TRIB3
through an E3 ligase and the latter to understand TRIB3 as a potential
regulator of the AKT signaling pathway. Salamanca proposed that
identifying and understanding PPIs in more detail would give novel
insight into biological processes and may lead to the development of
new therapeutic approaches and drugs.
4.5. Short talk on “Disturbing TRIB3/MDM2 interaction attenuates
pulmonary fibrosis by destabilizing transcription factor SLUG” by Dr.
Xiaoxi Lv and Best Poster on “Disrupting the TRIB3/p62 interaction
reduces liver fibrosis by restoring autophagic flux and suppressing
exosome-mediated HSC activation” by Dr. Xiaowei Zhang
Pulmonary fibrosis (PF) is the pathological origin of incurable
fibroproliferative lung diseases, but a few anti-PF therapeutics show
certain promise. Recent studies have suggested that chronic or repeated
lung injury causes failure of lung alveolar regeneration (LAR), which
then interferes with the resolution of PF and can lead to anti-PF therapy
resistance. Repetitive lung injury resulted in progressive accumulation
of the stress-induced protein TRIB3, which caused LAR failure by
interacting with E3 ligase MDM2 to suppress the ubiquitin-dependent
degradation of snail family transcriptional repressor 2 (SNAL2) in
alveolar epithelial cells. Disturbing the TRIB3/MDM2 interaction
might restore LAR capacity and exhibits potent therapeutic efficacy
against experimental PF. These findings suggested that TRIB3 play akey role on fibrotic diseases, which is consistent with Dr. Xiaowei
Zhang's recent hepatic fibrosis study, and Dr. Zhang received the Best
Poster Award at this meeting for presenting work on this topic.
Recently, it was found that human cirrhosis tissue expressed higher
levels of IL-17A, IL-17R and RORγt than control hepatic tissue.
Targeting IL-17A with a neutralizing antibody attenuated cholestatic
liver injury-induced hepatic fibrosis, restored hepatocyte autophagy
activity, and increased animal survival. In addition, IL-17A also
antagonism inhibited the phosphorylation of STAT3 in fibrotic tissues.
After blocking STAT3 with the STAT3 inhibitor STATTIC or after
Stat3 siRNA, IL-17A failed to suppress the autophagy in AML-12
cells, indicating that IL-17A inhibited autophagy induction by phos-
phorylating STAT348. The Trib3 gene promoter could be activated by
STAT3. Interestingly, the expression of TRIB3 was also much higher
in human cirrhosis tissues compared with control tissues, which
correlated positively with the expression of IL-17A. Moreover,
immunostaining and Co-IP revealed an interaction between TRIB3
and p62/SQSTM1, an autophagic receptor, which could cause p62
accumulation and obstruct the autophagy-proteasome pathway.
Accordingly, the anti-autophagy effect of IL-17A on hepatocytes
was reversed by silencing Trib3, which were consistent with the
in vivo findings that Trib3 depletion protected against BDL-induced
hepatic fibrosis, and restored hepatocyte autophagy activity. The
IL-17A-STAT3-TRIB3 signaling pathway played a crucial role in
the pathogenesis of hepatic fibrosis through regulating autophagy and
blocking this pathway may provide therapeutic benefits for the
treatment of hepatic fibrosis.
4.6. Plenary lecture on “Dissecting Tribbles signaling in C. elegans”
by Dr. Yishi Jin
Caenorhabditis elegans (C. elegans) is an excellent model to
investigate cellular stress responses including traumatic injury, neuro-
toxic stress, cytoskeletal stress and infection. Tribbles proteins are
highly conserved eukaryotic pseudokinases that function to control
kinase signaling and transcription in diverse biological processes,
including worms, where NIPI-3 is the single Tribbles homolog. C.
elegans Tribbles NIPI-3 was previously shown to activate host defense
upon infection by promoting the conserved PMK-1/p38 mitogen-
activated protein kinase (MAPK) signaling pathway. Despite the
prominent role of Tribbles proteins in many species, our knowledge
of their mechanism of action is fragmented, and the in vivo functional
relevance of their interactions with other proteins remains largely
unknown. The NIPI-3 null mutants characterizing studies showed that
NIPI-3 is essential for larval development and viability. Through
analyses of genetic suppressors of NIPI-3 null mutant lethality, they
found that NIPI-3 negatively controls PMK-1/p38 signaling via
transcriptional repression of the C/EBP transcription factor CEBP-1.
CEBP-1's transcriptional targets were identified by ChIP-seq analyses
and found to be enriched in genes involved in development and stress
responses49. Unlike its cell-autonomous role in innate immunity, NIPI-
3 is required in multiple tissues to control organismal development. Dr.
Yishi Jin concluded that NIPI-3 acts as a master regulator to inhibit
CEBP-1 and the PMK-1/p38 MAPK pathway, keeping innate
immunity in check and ensuring proper organismal development.
4.7. Plenary lecture on “Drosophila Tribbles identifies conserved
motifs regulating subcellular trafficking” by Dr. Leonard Dobens
The fruit flies are an ideal model system for Tribbles research. Flies
are useful to test conserved structure and various functions in
Bing Cui et al.450development and serve as a simplified system to screen for Tribbles
pathway components. The single TRIB pseudokinase gene (Trbl)
encodes a fly adaptor signaling protein that binds conserved targets
including AKT kinase and CDC25 (cell division cycle 25) phospha-
tase to block cell growth and division in response to developmental
and environmental signals50,51. Drosophila TRBL protein accumu-
lated in the nucleus, cytoplasm and at the cell membrane, where it
inhibited AKT phosphorylation to block insulin-mediated anabo-
lism50. Misexpression of a membrane-tethered form of AKT
(myr-AKT) resulted in strong mislocalization of TRBL to the inner
leaf of the fat body cell membrane, demonstrating that AKT binded
and recruited TRBL to the membrane in vivo. To identify domains in
the TRBL protein that mediate its trafficking among cellular
compartments, site-directed mutagenesis was used to identify a
conserved motif (‘ESLE286’) that when mutated resulted in a TRBL
protein that mislocalized strongly to the inner leaf of the cell
membrane; this was abrogated by RNAi knockdown of Akt. A TRBL
mutant (ESLE286G) was more stable than WT TRBL, an it more
effectively recruited a tagged-WT TRBL to the membrane to strongly
reduce cell growth and AKT phosphorylation-activation. An RNAi
knockdown screen identified insulin pathway components upstream,
downstream and in parallel to AKT that modulate the subcellular
localization of TRBL (ESLE286G). To identify new TRBL targets, Dr.
Leonard Dobens used a computer-based tool to measure the effect of
TRBL misexpression interactors and identified two E3 ubiquitin
ligases as candidate TRBL targets acting in a conserved Notch
signaling pathway regulating cell size and tissue growth.5. Session on “Tribbles and Cancer” chaired by Prof. Patrick
Eyers and Prof. Leonard Dobens
5.1. Key lecture on “TRIB2 acts as a major driver of tumorigenesis
and anti-cancer drug resistance” by Dr. Wolfgang Link
TRIB2 was identified as a novel oncogene in melanoma and as a
driver of anti-cancer drug resistance. Intrinsic and acquired
resistance to chemotherapy is the fundamental reason for treatment
failure for many cancer patients. The identification of the dynamic
molecular mechanisms involved in drug resistance or sensitization
is therefore imperative. It was reported that TRIB2 ablates fork-
head box O activation (FOXO) and disrupts the p53/MDM2
regulatory axis, conferring resistance to various chemotherapeutics
and targeted drugs. TRIB2 suppression was exerted via direct
interaction with AKT, a key signaling protein in cell proliferation,
survival and metabolism pathways. Ectopic or intrinsic high
expression of TRIB2 induced drug resistance by promoting
phospho-AKT (at Ser473) via its COP1 domain. TRIB2 expres-
sion was significantly increased in tumour tissues from patients
correlating with an increased phosphorylation of AKT, FOXO3a,
MDM2 and an impaired therapeutic response. This culminated in
an extremely poor clinical outcome. Dr. Wolfgang Link's study52
revealed a novel regulatory mechanism underlying drug resistance
and suggested that TRIB2 functions as a regulatory component of
the PI3K network, activating AKT in cancer cells.
5.2. Plenary lecture on “Insights into TRIB1, TRIB2 and TRIB3
pseudokinases in haemopoiesis” by Dr. Karen Keeshan
All three Tribbles pseudokinases (TRIB1, TRIB2 and TRIB3) are
important regulators of normal and malignant haemopoiesis1,6.
Moreover, the relative abundance of each tribbles family membermay be important for distinct oncogenic or tumour suppressor
functions1. The expression profiles of TRIB1, TRIB2 and TRIB3
were mapped in human and murine haemopoietic stem, progenitor
and mature cells and in human leukaemia datasets (Fig. 4). TRIB1-
TRIB2 have an inverse expression relationship in normal haemo-
poiesis whereas TRIB1-TRIB3 have a positive correlation. TRIB3
expression is high in the dormant haemopoietic stem cell (HSC)
population. These analyses supported a non-redundant role for
each Tribbles member during normal haemopoietic differentiation.
TRIB1-TRIB2 display a significant negative correlation in myelo-
dysplastic syndrome (MDS) and acute myeloid leukaemia (AML)
subtypes, but not in acute lymphoid leukaemia (ALL). This
inverse relationship is specific to certain subtypes of AML. A
positive correlation exists in different leukaemia subtypes between
TRIB1-TRIB3. Dr Karen Keeshan6,53 concluded that there were
significant differences in the range and variance of tribbles family
members expression, and these insights may be important for the
development of strategies to therapeutically target these genes in
different types of leukaemia.
5.3. Short talk on “How does TRIB3 promotes acute promyelocytic
leukemia and lymphoma progression?” by Dr. Ke Li
Acute promyelocytic leukemia (APL) is driven by the oncoprotein
PML-RARα that antagonizes myeloid differentiation and promotes
APL-initiating cell self-renewal. Either combing all-trans retinoic
acid (ATRA) with arsenic trioxide (ATO), or chemotherapy,
dramatically improves the prognosis of APL patients. Dr. Li
reported that expression of TRIB3 pseudokinase associated
positively with APL progression and therapeutic resistance. An
elevated TRIB3 expression promoted APL by interacting with
PML-RAR and suppressing its sumoylation, ubiquitylation
and degradation. This repressed PML nuclear body assembly,
p53-mediated senescence, cell differentiation, and supported
cellular self-renewal. Genetically inhibiting Trib3 expression or
combination of a peptide disturbing the TRIB3/PML-RAR inter-
action with ATRA/ATO eradicated APL by accelerating PML-
RAR degradation. This study provided new insight into APL
pathogenesis and suggests a new therapeutic option against APL7.
5.4. Plenary lecture on “Role of TRIB3 in the regulation of
cancer generation, progression and response to therapy” by
Dr. Guillermo Velasco
TRIB3 regulates cancer generation, progression and response to
therapy. Tribbles 3 is a member of the tribbles family of pseudo-
kinases, which lacks conventional kinase activity. TRIB3 participates
in the regulation of multiple signaling pathways that are involved in
different cellular processes like cell survival, proliferation or migra-
tion. Emerging data obtained during the last few years suggests that
TRIB3 is a crucial modulator of tumorigenesis. Recent observations
have shown that TRIB3 plays a tumor suppressor role in several
cellular and animal models of cancer through a mechanism that relies
on the regulation of the mTORC2/AKT axis54–56. In addition,
experiments performed with animal models showed that lesions in
the prostate of Ptenþ/ mice were enhanced by TRIB3 silencing57.
Dr. Guillermo Velasco58 then summarized their recent findings on
the role of TRIB3 in the regulation of breast cancer, hepatocellular
carcinoma and prostate cancer as well as on the role of this
pseudokinase in the regulation of autophagy-associated cancer cell
death in response to different stimuli.
Figure 4 Schematic depicting the expression inverse and correlative
relationship between TRIB1, TRIB2 and TRIB3 expression in
haemopoietic cells53.
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and progression by enhancing β-catenin/TCF4 transcriptional ac-
tivity” by Dr. Shuang Shang
Aberrant activation of the Wnt/β-catenin pathway plays a funda-
mental role in colorectal cancer (CRC) pathogenesis. Elevated
expression of TRIB3, a member of the tribbles family that is
upregulated in response to many stressors, has been reported to be
a negative prognostic marker of CRC, although the mechanism is
elusive. It was investigated that whether elevated TRIB3 expres-
sion promotes CRC stemness and progression by crosstalk with
WNT pathway. The initial results indicated that TRIB3 promotes
CRC tumorigenesis and progression in a PPI manner, which
provided proof-of-concept for targeting this PPI as a therapeutic
option against WNT-driven CRC59.5.6. Plenary lecture on “Transcriptional modulation by Trib1 in
myeloid leukemogenesis” by Dr. Takuro Nakamura
Trib1 acts as a dominant oncogene for hematopoietic cells and also
acts as a specific cooperative partner of Hoxa9 in myeloid
leukemogenesis60,61. Hoxa9 also cooperates with Meis1, resulting
in modification of target gene regulation and promotion of
leukemic cell engraftment and expansion in vivo62. It is therefore
of relevance to understand how the pseudokinase TRIB1 mod-
ulates HOXA9 activity during leukemia development. To clarify
the TRIB1's function in Hoxa9-associated AML, HOXA9-induced
leukemic cells derived from Trib1 KO bone marrow with or
without Trib1 overexpression were generated. Hoxa9-binding loci
are frequently associated with those of C/EBP in the absence of
Trib1 by ChIP-seq analysis. Given that TRIB1 induces degrada-
tion of C/EBP, it is predicted that TRIB1 may affect expression of
HOXA9-regulated genes. Indeed, expression of 1164 genes were
significantly upregulated in Trib1-overexpressing cells compared
to Trib1-null cells (FC42, Po0.05). Interestingly, ChIP-seq
analysis for histone H3K27Ac revealed that distribution of
super-enhancers was significantly modulated between two cell
types. Erg and Ptgds are upregulated genes in which H3K27Ac
signals are significantly increased by Trib1 overexpression.
Dr. Takuro Nakamura's results indicated that TRIB1 globally
modulated the transcriptional program of HOXA9 and induced
malignant phenotypes of AML.5.7. Short talk on “New insights into clinical development of
ABTL0812: a new antitumoral drug that induce autophagic cancer
cell death by upregulating TRIB3 pseudokinase” by Dr. Jose Lizcano
ABTL0812 is a novel, first-in-class, small molecule that shows
antiproliferative effects on tumor cells in phenotypic-based assays.
Prof. Jose Lizcano63 described the mechanism of action of this
antitumor drug, which is currently in clinical development.
ABTL0812 inhibited the AKT/mTORC1 axis, resulting in
impaired cancer cell proliferation and autophagy-mediated cell
death. In silico screening led Dr. Lizcano to identify the PPARs
termed PPARα and PPARγ as the cellular targets of ABTL0812.
He showed that ABTL0812 activated both PPAR receptors,
resulting in upregulation of TRIB3 gene expression. Upregulated
TRIB3 binded cellular AKT, preventing its activation by upstream
kinases, resulting in AKT inhibition and suppression of the AKT/
mTORC1 axis. Pharmacologic inhibition of PPARα/γ or TRIB3
silencing prevented ABTL0812-induced cell death. ABTL0812
treatment induced AKT inhibition in cancer cells, tumor
xenografts, and peripheral blood mononuclear cells in
patients enrolled in phase I/Ib first-in-human clinical trial.
ABTL0812 has a unique and novel mechanism of action, which
defines a new and druggable cellular route that links PPARs to
AKT/mTORC1 axis, where TRIB3 played a central role.
Dr. Lizcano concluded that activation of this route (PPARα/γ-
TRIB3-AKT-mTORC1) led to autophagy-mediated cancer cell
death. Given the low toxicity and high tolerability of ABTL0812,
their results supported further development of ABTL0812 as a
promising anticancer therapy.5.8. Plenary lecture on “Regulation of protein quality control as
a strategy for research and development of anticancer drugs” by
Dr. Zhuowei Hu
Cells detect and correct disordered proteomes through protein
quality control (PQC) systems, which maintain protein home-
ostasis under stress64. Cellular senescence is often accompanied
by a decrease in the ability of PQC. The accumulation of
impaired and misfolded proteins can cause cell death and
dysfunction. Autophagy and the proteasome system are the
core machinery of PQC systems to regulate the degradation of
different proteins and other biological macromolecules in cells.
This system maintains protein homeostasis in cells, playing key
roles in preventing oxidative stress and inflammation. Oncogen-
esis and multiple chronic inflammatory diseases involve the loss
of balance in intrinsic growth and cellular senescence. Abnor-
mal PQC contributes in an important way to the occurrence and
development of cancer and chronic inflammatory diseases.
Studies from Dr. Hu's team65,66 have shown that TRIB3 could
interact with autophagic cargo protein p62 to inhibit autophagic
flux and promoted the development of solid tumors (Fig. 5).
Furthermore, TRIB3 interacted with EGFR to promote its
membrane recycling and inhibit its degradation during the
malignant progression of lung cancer. Moreover, TRIB3 could
also interact with proto-oncogene the PML-RARα product, to
inhibit ubiquitin-proteasome activity and promote the develop-
ment of promyelocytic leukemia7. Based on these findings, Dr.
Hu's laboratory further demonstrated that the occurrence and
development of tumors could be prevented and controlled
through the regulation of the PQC function, offering a new
potential approach for the development of innovative drugs.
Figure 5 The role of TRIB3 in PML-RARα-driven leukemogenesis
and tumor progression. Metabolic stresses increase TRIB3 expression
to promote the interaction of TRIB3 and PML-RARα in APL cells, or
to enhance the binding of TRIB3 and p62 in tumor cells. TRIB3
interacts with PML-RARα to interfere with PML-RARα ubiquitylation
and degradation, which induces PML-RARα transcriptional activation
and promotes APL. The TRIB3-p62 interaction impedes the binding of
LC3 and ubiquitinated proteins to SQSTM1, which induces the
autophagic flux inhibition, subsequently defective ubiquitin protea-
some system (UPS). Dysfunction of two degradation systems result in
a genome instability and a deposition of cancer-promoting factors.
Thus, TRIB3 is critically involved in the pathogenesis of APL and
tumor progression. Targeting TRIB3 is a potential therapeutic option
for the treatment of cancer.
Bing Cui et al.4526. Summary
New findings reported at this meeting suggest that the TRIBs
pseudokinase proteins regulate a number of key signal transduc-
tion systems and PPIs, many of which are known to be
dysregulated in immune disease, metabolic disease or cancer1.
Several of the talks presented at the 2nd International Symposium
on Tribbles and Diseases reviewed recent important findings
examining the roles of TRIB pseudokinases in different diseases.
In the future, accurate dissection of the TRIB signaling machinery
will provide a much better understanding the different molecular
mechanisms controlled by TRIBs at specific stage of diseases,
including clarification of the oncogenic and tumor suppressive
functions of each of the individual TRIB proteins1,3. Cell perme-
able small molecules and PPI targeting peptides provide new
therapeutic opportunities for many TRIB-associated diseases,
including metabolic diseases and cancer7,63,65. The range of
exceptional presentations, subsequent questions and insightful
discussions will undoubtedly stimulate further studies on the
regulatory mechanisms underlying TRIB-mediated signal crosstalk
between metabolic tissues, immune cells and tumor cells, which
will ultimately help advance the fields of chronic inflammatory
diseases and cancer therapeutics.
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